Cullinan Oncology Valuation
| CGEM Stock | USD 13.09 0.32 2.51% |
At this time, the firm appears to be undervalued. Cullinan Oncology LLC shows a prevailing Real Value of $15.6 per share. The current price of the firm is $13.09. Our model approximates the value of Cullinan Oncology LLC from analyzing the firm fundamentals such as Return On Equity of -0.27, shares owned by insiders of 4.49 %, and Current Valuation of 186.57 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cullinan Oncology's valuation include:
Price Book 1.214 | Enterprise Value 186.6 M | Enterprise Value Ebitda (1.46) | Price Sales 26.8794 | Forward PE 6.3012 |
Undervalued
Today
Please note that Cullinan Oncology's price fluctuation is not too volatile at this time. Calculation of the real value of Cullinan Oncology LLC is based on 3 months time horizon. Increasing Cullinan Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cullinan stock is determined by what a typical buyer is willing to pay for full or partial control of Cullinan Oncology LLC. Since Cullinan Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cullinan Stock. However, Cullinan Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.09 | Real 15.6 | Target 24.6 | Hype 13.8 |
The intrinsic value of Cullinan Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cullinan Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cullinan Oncology LLC helps investors to forecast how Cullinan stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cullinan Oncology more accurately as focusing exclusively on Cullinan Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cullinan Oncology's intrinsic value based on its ongoing forecasts of Cullinan Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cullinan Oncology's closest peers.
Cullinan Oncology Cash |
|
Cullinan Valuation Trend
Knowing Cullinan Oncology's actual value is paramount for traders when making sound investment determinations. Using both Cullinan Oncology's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Cullinan Oncology Total Value Analysis
Cullinan Oncology LLC is currently forecasted to have valuation of 186.57 M with market capitalization of 762.2 M, debt of 3.59 M, and cash on hands of 611 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cullinan Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
186.57 M | 762.2 M | 3.59 M | 611 M |
Cullinan Oncology Asset Utilization
One of the ways to look at asset utilization of Cullinan is to check how much profit was generated for every dollar of assets it reports. Cullinan Oncology LLC shows a negative utilization of assets of -0.2 percent, losing $0.00204 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cullinan Oncology LLC shows how discouraging it operates for each dollar spent on its assets.Cullinan Oncology Ownership Allocation
The majority of Cullinan Oncology LLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cullinan Oncology LLC to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cullinan Oncology. Please pay attention to any change in the institutional holdings of Cullinan Oncology LLC as this could imply that something significant has changed or is about to change at the company.Cullinan Oncology Profitability Analysis
Net Loss for the year was (153.16 M) with profit before overhead, payroll, taxes, and interest of 18.94 M.About Cullinan Oncology Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Cullinan Oncology LLC. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cullinan Oncology LLC based exclusively on its fundamental and basic technical indicators. By analyzing Cullinan Oncology's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Cullinan Oncology's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cullinan Oncology. We calculate exposure to Cullinan Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cullinan Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -310 K | -294.5 K | |
| Pretax Profit Margin | (3.21) | (3.37) | |
| Operating Profit Margin | (3.23) | (3.39) | |
| Net Loss | (3.09) | (3.24) | |
| Gross Profit Margin | 0.90 | 0.80 |
Cullinan Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cullinan Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 41.5 M | |
| Forward Price Earnings | 6.3012 |
Cullinan Oncology Current Valuation Indicators
Cullinan Oncology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Cullinan Oncology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cullinan Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cullinan Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cullinan Oncology's worth.When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.